BREAKING NEWS! Amolyt Pharma, a CTI Life Sciences Fund portfolio company, enters into a definitive agreement to be acquired by AstraZeneca for $1.05B. The deal includes a $800M upfront payment and a near-term $250M milestone. Congratulations to Thierry Abribat and the whole team on this amazing achievement! Amolyt Pharma is developing best-in-class therapeutic peptides for the treatment of underserved rare endocrine diseases. Its lead asset, Eneboparatide (AZP-3601), is an investigational daily subcutaneous injectable parathyroid hormone receptor 1 (PTHR1) agonist for the treatment of hypoparathyroidism, currently in Phase 3. We are excited about AstraZeneca taking this best-in-class asset forward to help patients with hypoparathyroidism. CTI Life Sciences Fund participated in Amolyt Pharma's Series C last year. A special shout out to Laurence Rulleau,PhD for her leadership on this deal. https://lnkd.in/ejXx6KWk
Congrats to the team!
Félicitations Laurence et à l'équipe CTI
Congrats Laurence and CTI Life Sciences Fund team!
Bravo Laurence!
Merci Didier!
Bravo Laurence et l’équipe CTI Lifesciences. Une excellente nouvelle et une belle réussite.